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Abstract: Desertomycin A is an aminopolyol polyketide
containing a macrolactone ring. We have proposed that
desertomycin A and similar compounds (marginolactones)
are formed by polyketide synthases primed not with g-amino-
butanoyl-CoA but with 4-guanidinylbutanoyl-CoA, to avoid
facile cyclization of the starter unit. This hypothesis requires
that there be a final-stage de-amidination of the corresponding
guanidino-substituted natural product, but no enzyme for such
a process has been described. We have now identified candidate
amidinohydrolase genes within the desertomycin and primycin
clusters. Deletion of the putative desertomycin amidinohydro-
lase gene dstH in Streptomyces macronensis led to the
accumulation of desertomycin B, the guanidino form of the
antibiotic. Also, purified DstH efficiently catalyzed the in vitro
conversion of desertomycin B into the A form. Hence this
amidinohydrolase furnishes the missing link in this proposed
naturally evolved example of protective-group chemistry.
Complex polyketides are among the most numerous and
structurally diverse bacterial natural products, and they
include compounds of outstanding clinical effectiveness,
either as antibiotics, immunosuppressants, or antitumor com-
pounds.[1] They are biosynthesized by polyketide synthase
(PKS) multienzymes according to a remarkable assembly-line
paradigm, in which each cycle of polyketide chain extension is
accomplished by a different set or module of fatty acid
synthase (FAS)-related enzyme domains.[2] This provides
a direct link between gene sequence and the structure of
the chemical product, which means that if a strain is
discovered to produce a specific compound, it is now
a straightforward procedure to identify the corresponding
gene cluster that encodes its biosynthesis. Recent dramatic
advances in whole-genome sequencing also make it possible
to make reasonable predictions of the biosynthetic potential
of each strain, thereby leading to broad insight into the
biogenesis of all major classes of polyketide, and opening the
way to “genome mining” for novel compounds.[3] There is
great interest in developing methods of biosynthetic engi-
neering, in partnership with medicinal chemistry, to introduce
additional chemical diversity into these molecules.[4]
Desertomycin A (1a, Scheme 1) is a member of the
marginolactones, antifungal macrocyclic polyketides substi-
tuted with either an amino or a guanidino group and
possessing a ring size of 31 carbon atoms or more.[5] We
have recently shown that 4-guanidinobutanoyl-CoA derived
from l-arginine provides the starter unit for azalomycin F (4,
Scheme 1) biosynthesis.[6] Biosynthesis of the amino-contain-
ing marginolactones has been suggested to follow an analo-
gous pathway from ornithine,[5,7] but we have previously
proposed an alternative hypothesis, in which amino margin-
olactones are derived from their guanidino-substituted coun-
terparts in a deprotection[8, 9] step catalyzed by an amidinohy-
drolase as a late step in biosynthesis. The biosynthetic gene
cluster for the aminopolyene ECO-02301 has been reported
to contain a gene for a potential amidinohydrolase enzyme.[10]
We report herein a genome-based approach to identifying and
characterizing amidinohydrolases acting in marginolactone
biosynthesis, and we show that the novel amidinohydrolase
DstH is indeed necessary and sufficient for the deprotection
of desertomycin B[11] to form desertomycin A. Our results set
the stage for a detailed examination of marginolactone
biosynthesis, and reveal a new possibility for the designed
incorporation of a chemically reactive amino functionality
into complex polyketides.
We selected for genome sequence analysis three known
desertomycin A producing strains: Streptomyces olivaceus
Tî4018, which also produces the 36-membered marginolac-
tone kanchanamycin (3, Scheme 1),[12] Streptomyces macro-
nensis,[13] and Streptomyces spectabilis.[14] We also determined
high-quality whole-genome sequences for Saccharomono-
spora azurea (syn. S. caesia), which produces the 36-mem-
bered arabinosyl marginolactone primycin (2, Scheme 1),[15]
and for Streptomyces violaceusniger DSM4137[16] which
produces the guanidino marginolactone azalomycin F.[17]
Using a previously characterized arginine oxidase gene[6]
from the S. violaceusniger strain as a probe, all six target
gene clusters were located within their respective genome
sequences. The desertomycin gene cluster in S. olivaceus and
the primycin gene cluster in S. azurea are arranged as shown
in Scheme S1 in the Supporting Information. Detailed
information about each gene is given in the Supporting
Information (Tables S4–S9) for all clusters. The arrangement
of enzymatic domains within each modular PKS (Figures S1
and S2 in the Supporting Information), and the predicted
configuration of the full-length polyketide chains (Figure S3),
were deduced by using previously validated sequence motifs
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in each type of domain: acyltransferase (AT),[18] ketoreduc-
tase (KR),[19] dehydratase (DH),[20] and enoylreductase
(ER)[21] domains. For primycin and desertomycin,[22,23] there
is (almost) exact correspondence between the enzyme
arrangement in each extension module and the chemical
structure of the polyketide product. In contrast, for both
azalomycin and kanchanamycin PKSs, 20 cycles of chain
extension are apparently accomplished by only 19 extension
modules. In these gene clusters, the first multienzyme in the
PKS assembly line (AzlA1 and KchA1 respectively), which
contains the loading acyl carrier protein and the first
extension module, appears to carry out both the first and
second cycles of chain extension. Such programmed iterative
use of a PKS module is unusual but not unprecedented.[24]
Also, the structure of these two marginolactones requires full
reduction by extension module 3, yet neither PKS possesses
an ER domain in that module. Work is in progress to
determine the mechanisms involved. Only for desertomycin
has the absolute configuration been experimentally estab-
lished.[23, 25] Comparison of this with the configuration pre-
dicted from the PKS structure (Figures S1–S3) showed exact
agreement, except for the configuration at C-30, which is
reversed from that predicted.
The desertomycin-, primycin-, and kanchanamycin-pro-
ducing strains were all found, upon LC–MS analysis of
fermentation extracts, to produce a mixture of guanidino and
amino forms (Figures S4–S6 and Tables S10,S12,S13). For
desertomycin, the amino form is by far the major form, while
for primycin and kanchanamycin, both forms contribute
significantly. In contrast, azalomycins were never detected in
amino form (Figure S7). As indicated in Scheme S1 and
Table S4, an open reading frame (dst6277, hereinafter
referred to as dstH) that is co-located with the polyketide
synthase region of the desertomycin gene cluster in S.
macronensis is predicted, on the basis of sequence compar-
isons with public databases, to encode an enzyme in the
ureohydrolase superfamily (Figure S8). The ureohydrolase
superfamily embraces diverse agmatinases, arginases, guani-
dinobutyrases, formiminoglutamase, and proclavaminate
hydrolase.[26] The mechanism of these enzymes involves
nucleophilic attack on the amidino carbon by a hydroxide
ion bridging two divalent metal ions.[26]
It cannot be ruled out that a uniquely essential biosyn-
thetic gene is encoded elsewhere than in the main biosyn-
thetic gene cluster.[27] However, our interest in the putative
amidinohydrolase DstH was strengthened by the finding that
it shares 56% (76%) amino acid identity (similarity) with
PriH, the product of a gene in the primycin gene cluster
immediately adjacent to the PKS region (Scheme S1 and
Table S8). Sequence alignment of DstH and PriH with
authentic ureohydrolases in the Protein Data Bank (PDB)
protein structure database (Figure S8A) revealed that DstH
and PriH contain the sequence motifs xGGDH, DAHxD, and
SxDxDxxDPxxxP (where x= any amino acid), which are
conserved in this enzyme superfamily and are implicated in
cation binding and catalysis.[26] To study the possible role of
DstH in desertomycin biosynthesis, we created an in-frame
deletion in the dstH gene in S. macronensis (Figure S9), as
described in the Supporting Information. The resulting
mutant strain DdstH was grown in liquid culture and analyzed
for the production of desertomycins by HPLC–MS. Deserto-
mycin A production was found to be completely abolished in
this strain, and instead a new species was detected with
a retention time later by 0.8 min, and with m/z [M+H]+
1234.7, which corresponds to the molecular ion for the
guanidino form of the antibiotic. This compound, desertomy-
cin B (1b ; Figure 1A) was originally described as a minor
fermentation product of Streptomyces flavofungi.[11] Its iden-
tity was confirmed by MS/MS and high-resolution MS
analysis (Figure S4 and Tables S10,S11). The level of deser-
tomycin B produced by the mutant is the same as that of
Scheme 1. Structures of the antifungal marginolactones desertomycin
(1), primycin A1 (2), kanchanamycin C (3), and azalomycin F4a (4).
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desertomycin A in the wild type. This finding strongly
supports a mechanism for the production of desertomycin A
in which the amidino group is hydrolyzed to liberate the
amino form as the last step in the biosynthetic pathway. It also
convincingly identifies DstH as the essential and sufficient
catalyst for this conversion in vivo. Minor amounts were
detected of a putative positional isomer of desertomycin A,
labeled 1a* in Figure 1, and this species was likewise replaced
in the mutant strain by 1b*. To confirm the role of DstH, the
gene for this enzyme was cloned and expressed in recombi-
nant E. coli and purified to near homogeneity (Figure S10).
Desertomycin B was purified from the DdstH mutant of S.
macronensis and tested as a substrate for the enzyme. In the
presence of an appropriate divalent metal ion (cobalt, nickel)
desertomycin B was efficiently converted into desertomy-
cin A, as judged by LC–MS analysis and comparison with
authentic material (Figure 1B and Figure S11). Kanchana-
mycin C (3 ; guanidino form) was purified from extracts of S.
olivaceus Tî4018 and also tested as a substrate for DstH. The
kch gene cluster of S. olivaceus does not contain an analogue
of DstH or PriH, so it seemed possible that the DstH enzyme
encoded in the desertomycin cluster of the same strain might
show crosstalk and be able to perform the final-stage
deprotection of kanchanamycin to the amino form. In
accord with this idea, kanchanamycin proved to be a good
substrate for DstH with
each the added divalent
metals tested (Co2+, Ni2+,
Zn2+, Mg2+, Mn2+; Fig-
ure 2B and Figure S13).
However, further work will
be required to establish the
exact identity and status of
active-site metal ions in
DstH.
Azalomycin is almost
identical to kanchanamy-
cin, except that the major
form of azalomycin (4, aza-
lomycin F4a) produced by
S. violaceusniger DSM4137
is methylated on the guani-
dino group. Azalomy-
cin F4a was not a substrate
for purified DstH (Fig-
ure S14), thus implying
that methylation prevents
unmasking of the primary
amino group. Given the
high sequence identity
between DstH and PriH,
we predicted that DstH
would also act on primy-
cins.[15b] Primycin A1 (2)
was purified from S. caesia
and incubated with DstH in
the presence of Co2+ or
Ni2+, where it gave almost
complete conversion of
guanidino primycins into the corresponding amino forms
(Figure 2A and Figure S12). Therefore DstH amidinohydro-
lase is flexible enough to accept different macrocyclic
polyketides as substrates. This in turn suggests the possibility
that, if the guanidinobutanoate starter unit were in the future
successfully grafted onto a different macrocyclic polyketide
by biosynthetic engineering, DstH or another natural amidi-
nohydrolase could be used in a mild enzymatic deprotection
step to expose the primary amino function for selective
chemical derivatization.
It is instructive to compare the marginolactone pathway
proposed herein with butirosin[8] and vicenistatin[9] biosyn-
thesis, where a protective-group strategy has also been
proposed to prevent thioester intermediates being inter-
cepted by intramolecular nucleophilic attack from a primary
amine (Scheme 2). It might be argued that, for example, non-
ribosomal peptide synthetases (NRPSs) recruit unprotected
amino acids and yet use thioester chemistry,[28] and modular
polyketide synthases are also known that recruit free
aromatic[29] or aliphatic[30] amino-substituted building blocks.
However, the three cases in Scheme 1 are distinguished from
these other examples by the fact that cyclization of specific
amino-substituted thioester intermediates would proceed
through the chemically facile formation of either a 5- or a 6-
membered ring. For butirosin (Scheme 2A), g-aminobuta-
Figure 1. HPLC–MS analysis of desertomycins A (1a) and B (1b). A) LC–ESI-MS total ion current traces for
mycelium methanol extracts from S. macronensis wild type and the DdstH deletion mutant. In the mutant,
production of 1a was abolished and replaced by guanidino compound 1b. Inserts show mass spectra of
[M+H]+ ions for 1a (1192.7) and 1b (1234.7). The 13.02 min and 14.27 min peaks labeled as 1a* and 1b*
have the same MS and MS/MS as 1a and 1b, respectively, and may represent isomers of 1a and 1b of altered
ring size, although this remains to be established. B) LC–ESI-MS total ion current traces of DstH-catalyzed
conversion of desertomycin B 1b (and putative isomer 1b*) into desertomycin A 1a (and putative isomer
1a*) when Co2+ is present as the activating metal ion.
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noyl-BtrI is the vulnerable acyl-
ACP intermediate, and for deserto-
mycin (Scheme 2C), the same
hypothetical unprotected acyl-ACP
starter unit would initiate poly-
ketide assembly. For vicenilactam,
the aglycone core of vicenistatin,
the PKS-bound thioester intermedi-
ate after the first cycle of chain
extension (Scheme 2B) would sim-
ilarly favor cyclization if it were not
protected by the addition of an N-
terminyl l-Ala unit. In fact, inter-
mediates attached to peptidyl car-
rier protein (PCP) domains on
NRPSs are well known to suffer
side reactions when cyclization is
sterically favored, especially in the
formation of cyclodipeptides.[31]
Ornithinyl-PCP thioesters are espe-
cially liable to this side reaction,
presumably because cyclization
occurs through attack of a primary
amine on a thioester via a 6-mem-
bered transition state to form 3-
amino-2-piperidone. The formation
on the gramicidin S synthetase
NRPS of both cyclo-ornithine[32]
and cyclo-ornithinyl peptides[33]
has been demonstrated. Spencer
Figure 2. HPLC–MS analysis of in vitro assays with DstH. A) LC–ESI-MS total ion current traces of
DstH-catalyzed conversion of primycin A1 (2) into the amino form. (B) LC–ESI-MS total ion current
traces of DstH-catalyzed conversion of kanchanamycin C (3) into the amino form. For the assays
shown, Co2+ was the metal ion present. For assays with Ni2+, Zn2+, Mg2+, and Mn2+ as the activating
metal ion, see Figures S12,S13.
Scheme 2. Examples of a protective-group strategy in the biosynthesis of the natural products butirosin (A); vicenilactam (B), the aglycone core of
vicenistatin; and desertomycin (C). Each pathway has at least one intermediate (relevant portion shown in bold) that, unless protected, would be
vulnerable to facile cyclization via a five- or six-membered cyclic transition state.
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and colleagues in their studies on butirosin reported insta-
bility of 4-aminobutanoyl-CoA in solution.[8] In contrast, 4-
guanidylbutanoyl-CoA and 4-guanidinylbutanoyl-ACP are
both stable in neutral aqueous buffers at room temperature.[6]
It would appear that protective-group chemistry in biosyn-
thetic pathways only evolves where it is most needed.
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